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In 10 patients with moderate to severe hypertension, the
hemodynamic effects of ergometric exercise and nicar-
dipine, a dihydropyridine calcium channel antagonist,
were characterized under basal conditions and after 1
week of therapy, The responses of plasma renin activity
and catecholamines were also assessed. Nicardipine in-
duced significantreductions of systolic,diastolicand mean
blood pressure under conditions of rest and peak exercise
(p < 0.001), mediated by reversal of vasoconstriction (p
< 0.001). Overall, cardiac index and stroke volume in-
dex responses were not significantly altered by nicard-
ipine. Although rest pulmonary wedge pressure was un-
changed (6 ± 3 to 5 ± 4 mm Hg), peak exercisepulmonary
wedge pressure decreased from 24 ± 22 to 7 ± 5 mm
Hg (p < 0.001) with nicardipine therapy. This effect of
nicardipine on pulmonary wedge pressure was present
Stressing the cardiovascular system during graded exercise
provides a feasible clinical approach to increase understand-
ing of the cardiovascular adaptation of systemic hyperten-
sion, and the subsequent response to therapeutic interven-
tions, beyond the information obtained when only rest
variables are assessed. Additional information can be ob-
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across all work loads studied, and was accompanied by
reduction of peak exercise pulmonary artery pressure
from 43 ± 10 to 25 ± 7 mm Hg (p < 0.001). Oxygen
consumption was unchanged, associated with reduction
of arteriovenous oxygendifference (p < 0.02). Both plasma
renin activity (p < 0.05) and norepinephrine (p < 0.005)
were significantly increased with nicardipine therapy.
Thus, nicardipine produced significant blood pres-
sure reduction by reversal of vasoconstriction in patients
with essential hypertension. The preservation of cardiac
output, with markedly reduced pulmonary wedge pres-
sure, indicated that nicardipine improved ventricular
performance in response to reversal of vasoconstriction.
(J Am Coli CardioI1987;10.·647-54)
tained using invasive techniques, including measurement of
pulmonary wedge pressure, so that pulmonary hemody-
namics and the loading characteristics of the ventricle can
be described. However, only a small number of studies in
hypertension ( 1-3) have reported these characteristics under
exercise conditions, particularly as they relate to therapeutic
interventions.
This approach to hemodynamic evaluation is of particular
interest for the calcium channel antagonists. This class of
agents produces a favorable antihypertensive effect (4-6);
yet there are at least three direct cardiovascular effects that
may influence the overall antihypertensive response: potent
direct vasodilatation (7-9), improvement of ventricular iso-
volumic relaxation (10, II) and a negative myocardial ino-
tropic effect (12,13). As a class of drugs, the calcium chan-
nel antagonists may be rather heterogeneous in terms of
these effects (14). For instance, nicardipine, a second gen-
eration dihydropyridine, is reported (15,16) to have a min-
imal negative inotropic effect despite potent vasodilator ac-
tivity. We therefore evaluated the hemodynamic response
to graded exercise, and the effect of I week of oral nicar-
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dipine therapy in patients with moderate to severe systemic
hypertension.
Methods
Study patients. The study group comprised 10 patients
with moderate to severe hypertension. There were seven
men and three women, ranging from 27 to 76 years of age.
All patients had essential hypertension, on the basis of stan-
dard screening criteria, documented during outpatient visits
over at least 2 years. All patients had been receiving one
or more combinations of medical therapy with unsatisfactory
blood pressure control. No patient manifested accelerated
or malignant hypertension or had clinical evidence of
congestive heart failure or chronic lung disease. Fundus-
copic changes ranged from grade I through III hypertensive
retinopathy. Occlusive carotid disease was excluded by
physical examination and Doppler ultrasound evaluation.
No patient provided a history of angina or myocardial in-
farction, had ever been treated with an antianginal regimen
or had electrocardiographic (ECG) evidence of myocardial
infarction.
Previous medications were tapered and discontinued in
the I to 3 week period before admission to the hospital to
avoid carryover effects of previous therapy. All patients
were admitted to the Adult Clinical Research Center of New
York Hospital-Cornell Medical Center for the study and
were maintained on a 100 mEq sodium diet. Informed writ-
ten consent was given, and the study was approved by the
Committee on Human Rights in Research.
Overall study design. After admission to the Clinical
Research Center, patients were observed for 3 to 5 days of
stabilization. They then underwent two exercise hemody-
namic studies performed I week apart. During the first
hemodynamic study, exercise responses in the baseline un-
treated state were obtained. The second study was performed
after 1 week of oral nicardipine therapy. All hemodynamic
studies were performed in the morning, after an overnight
fast. Patients were brought to the hemodynamic procedure
room, where a right heart catheter was placed percuta-
neously from either an arm vein or an internal jugular vein,
and a cannula was placed percutaneously into a brachial
artery. A I to 2 hour equilibration period ensued, followed
by the baseline upright exercise. After baseline study, oral
therapy with nicardipine was initiated at a dose of 30 mg
administered every 8 hours. After I week of oral nicardipine
therapy, and maintenance of the 100 mEq sodium diet, the
patients returned to the procedure room for repeat exercise
hemodynamic study, using the contralateral arm for catheter
placement.
Exercise hemodynamic protocol. The hemodynamic
studies were performed on a table designed for upright ex-
ercise as previously described (3). The patients were placed
in a seated position in which they could comfortably pedal
an electronically braked bicycle ergometer attached to the
table. Patients rested in the seated position for 15 minutes
and were then connected by a one-way breathing mask to
a metabolic cart (Sensor Medics) for continuous analysis of
expired gases for oxygen consumption (Vo2) and carbon
dioxide production (Vco-). We also measured heart rate,
pressures and cardiac output and obtained blood samples
for determination of plasma renin activity, norepinephrine
and simultaneous arterial and pulmonary artery oxygen sat-
uration. After these baseline values were obtained, exercise
began at a work load of 25 Wand increased by 25 W
increments every 3 minutes until limited by exhaustion.
Hemodynamic monitoring and analysis of expired gases
were performed continuously throughout each stage of ex-
ercise with cardiac output determined in the last minute of
each stage. Peak exercise was defined as the occurrence of
patient exhaustion, provided that the respiratory exchange
ratio (Veo2!V02) was >0.95, a level consistent with peak
aerobic muscle metabolism and maximal exertion (17,18).
At the peak exercise response, we also obtained blood sam-
ples for plasma renin activity and norepinephrine and si-
multaneous arterial and mixed venous oxygen saturation.
When patients had recovered from exercise, the catheters
were removed and the exercise protocol was terminated.
Determination of hemodynamic and respiratory gas
variables. Heart rate and all pressures were recorded con-
tinuously throughout the study on a multichannel recorder.
The heart rate was obtained from a standard limb lead elec-
trocardiogram (ECG). The reference point for pressure
transducers was the level of the right atrium in the midax-
illary line. Pressures were tracked as both phasic and elec-
tronically filtered mean recordings, with use of the latter
for calculation of derived indexes. Arterial blood pressure
was recorded as systolic, diastolic and mean. The heart rate-
systolic blood pressure product was also calculated. We also
recorded pulmonary artery and right atrial pressures contin-
uously. Phasic and mean pulmonary wedge pressures were
obtained at the end of the rest phase and just before the last
minute of each stage of exercise. Cardiac output was de-
termined by thermodilution, in triplicate, using 10 ml of
iced dextrose in water injectate, and was expressed as car-
diac index (liters/min per rrr'), correcting for body surface
area. Stroke volume index was obtained by dividing cardiac
index by the heart rate. Systemic vascular resistance and
pulmonary vascular resistance were calculated from stan-
dard formulas (19). Expired gases were analyzed on a met-
abolic cart with Beckman analyzers (SensorMedics).
Blood sample analysis. Plasma renin activity was es-
timated by radioimmunoassay as previously described (20).
Plasma norepinephrine and epinephrine were analyzed by
the radioenzymatic method of Peuler and Johnson (21), with
values expressed as picograms per milliliter. Analysis of
blood oxygen saturation (Sao.) was by transmission spec-
trophotometry, and blood oxygen content (Cao2) was cal-
culated from the formula Cao, = Sao, x hemoglobin x
1.34, expressed as volume percent. The arteriovenous ox-
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ygen difference was calculated as the difference of arterial
and mixed venous oxygen content.
Statistical analysis. Statistical analysis for hemody-
namic and hormonal data was by two-way analysis of var-
iance (22). We determined the within-group influence of
activity (rest versus peak exercise) and treatment (baseline
versus nicardipine), as well as potential interactions (23).
Differences were considered significant at a level of <0.05.
Significance values beyond the <0.001 level were assigned
the value of <0.00 I. For clarity, the analysis results for the
nicardipine treatment effect are shown in the figures only,
and the activity effect is described only in the text. We also
evaluated the effect of nicardipine on pulmonary wedge
pressure, over all work loads studied, using paired analyses
following the Bonferroni adjustment of the probability (p)
value corrected for multiple determinations. All values rep-
resent the mean ± I SD.
Results
Hemodynamic responses to exercise (Fig. 1 to 3). In
the untreated state, maximal ergometric exercise was as-
sociated with an increase of heart rate from 72 ± 13 to 152
± 17 beats/min and mean arterial pressure increased from
142 ± 18 to 183 ± 23 mm Hg (both p < 0.001). The
increase in mean arterial pressure was reflected in both the
systolic and diastolic components. Systolic blood pressure
increasedfrom211 ± 35t0312 ± 56mmHg(p<O,OOI),
and diastolic blood pressure from III ± 16 to 124 ± 24
mm Hg (p < 0.03). The rate-pressure product increased
from 15,053 ± 3,612 to 46,873 ± 8,401 (p < 0.001; not
shown in the figure). The blood pressure response to exercise
was accompanied by an increase of right atrial pressure (4
± 4 to 7 ± 6 mm Hg; p < 0.05), pulmonary artery pressure
(17 ± 4 to 43 ± 10 mm Hg; p < 0,001) and pulmonary
wedge pressure (6 ± 3 to 24 ± II mm Hg; p < 0.001).
In the untreated state, exercise resulted in an increase of
cardiac index from 2.44 ± 36 to 6.99 ± 1.32 liters/min
per m? and of stroke volume index from 35 ± 7 to 47 ±
9 ml/rrr' (both p < 0.001). Systemic vascular resistance
decreased in response to exercise from 2,304 ± 644 to
1,061 ± 434 dynes.s.cm- 5 (p < 0.001), whereas the de-
crease of pulmonary vascular resistance from 191 ± 101
to 117 ± 63 dynes-s-cm -- 5 was not significant.
Effect of nicardipine on exercise hemodynamics (Fig.
1 to 3). Heart rate increased from 91 ± 19 to 153 ± 28
beats/min during exercise, with no significant treatment ef-
fect. The increase of rest heart rate compared with baseline
(72 ± 13 beats/min) was significant (p < 0.03). Mean
arterial blood pressure was 108 ± 13 mm Hg at rest, in-
creasing to 142 ± 23 mm Hg at peak exercise; these were
significantly decreased compared with pretreatment values
15 NIC ns
Figure 2. The effect of exercise (Ex) and nicardipine (Nic) on
rightatrial pressure(RAP), mean pulmonary artery pressure(PAP)
and pulmonary wedge pressure (PWP). Nicardipine therapy re-
sulted in markedreductionof exercisepulmonary arteryand wedge
pressures. R = rest. (e) Baseline; (0) nicardipine.
RAP
mmHg











60 120 -""j----.----------r- mmHg
R Ex R Ex 20
0
Nic <.001 Nic <.001 R Ex
200 ~. 130~ NIC<,00140MAP 160 DBP 110 ..mmHg mmHg PWP 24120~ 90 mmHg 880 70 -,---- 0
R Ex R Ex R Ex
Figure 1. The responseof heart rate (HR), systolicbloodpressure
(SBP), mean arterial pressure (MAP) and diastolic blood pressure
(OBP), comparing seated rest (R) and peak exercise (Ex) effects.
The significance values shown in this figure and Figures2 through
4 represent the statistical analysis of the nicardipine (Nic) effect
on hemodynamics by two-way analysis of variance; the exercise
effect is stated in the text. There was no significant overall effect
of nicardipine on heart rate; rest heart rate was increased (p <
0.03) compared with pretreatment. Nicardipine therapy was as-
sociated with a marked reduction of systolic, mean and diastolic
blood pressures. All values represent mean values ::': 1 SO. (el
Baseline; (0) nicardipine.
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Figure3. Theresponse ofcardiac index (Cl),stroke volume index
(SYI), systemic vascular resistance (SYR) andpulmonary vascular
resistance (PYR) to exercise (Ex) and nicardipine (Nic) therapy.
Although there was no significant effect of nicardipine on cardiac
index or stroke volume index, there was an interaction (p < 0.02)
of nicardipine and exercise 011 cardiac index due to the increase
ofrest (R) cardiac index (mediated byheart rate) during nicardipine
therapy. The significant reduction of systemic vascular resistance
by nicardipine accounted for the reduction of arterial blood pres-
sure. The response of pulmonary resistance was less uniform, so
that significance was notachieved. (e) Baseline; (0) nicardipine.
0.77, increasing to 6.36 ± 0.92 liters/min per m". An
activity-treatmentinteraction (p < 0.02) was observed, rep-
resenting differences of rest cardiac index comparing base-
line (2.44 ± 0.36 liters/min per rrr') and nicardipine (3.30
± Q.77 liters/min per m2) values. Stroke volume index was
37 ± 10 ml/rrr' at rest, increasing to 43 ± 10 ml/rrr' at
peak exercise (p = NS, compared with pretreatment). In
contrast, there was a marked effect of nicardipine therapy
on the response of systemic vascular resistance to exer-
ise. At rest, systemic vascular resistance was 1,326 ± 314
dynes-s-cm" 5, decreasing to 872 ± 212 dynes-scm r " dur-
ing peak exercise. This effect was highly significant (p <
0.001), demonstrating an activity-treatmentinteraction (p <
0.01). Although there was a modest reduction of pulmonary
vascular resistance at rest (143 ± 107 dynes-s-cm - 5), with
a further small reduction during exercise (120 ± 83), this
did not achieve statistical significance.
Characteristics of respiratory gas exchange (Fig. 4).
In the baseline untreated state, oxygen consumption in-
creased from 281 ± 51 to 1,645 ± 489 mllmin, and carbon
dioxide production from 212 ± 40 to 1,797 ± 506 mllmin
(both responses p < 0.01). Nicardipine therapy had no
significant effect on these values at rest or peak exercise,
so that the peak exercise respiratory exchange ratio was not
changed. However, there was a reduction of the arterio-
Figure4. Neither oxygen consumption (Yo2) norcarbon dioxide
production (YC02) was appreciably altered by nicardipine (Nic).
However, there was a significant decrease of both rest (R) and
peak exercise (Ex) arteriovenous oxygen difference (AYo2D) dur-
ing nicardipine therapy that was consistent with a reduction of





(p < 0.00 I). The reduction of mean arterial pressure was
reflected in systolic blood pressure, which was 175 ± 26
at rest, increasing to 240 ± 51 mm Hg during exercise;
likewise, diastolic blood pressure was 84 ± 14, increasing
to 96 ± 15 mrn Hg. The effect of nicardipine on systolic
and diastolic blood pressure was statistically significant (both
p < 0.001). The rate-pressure product was 15,675 ± 2,448
(rest) and 35,784 ± 5,833 (exercise), representing a ni-
cardipine effect of p < 0.05.
Right atrial pressure during therapy was 2 ± 3 at rest,
increasing to 4 ± 5 mm Hg at peak exercise (p = NS
compared with pretreatment value [Fig. 2]). The rest value
for pulmonary artery pressure (15 ± 7 mm Hg) was es-
sentially unchanged during nicardipine therapy; during peak
exercise, the value increased to 25 ± 7 mm Hg (p < 0.001
compared with baseline, with a significantactivity-treatment
interaction of p <'0.001). In a similar pattern, pulmonary
wedge pressure at rest was 5 ± 4 mm Hg during nicardipine
therapy, with a marked reduction to 7 ± 5 mm Hg at peak
exercise (p < 0.001 compared with baseline with an activity-
treatment interaction of p < 0.001).
The effect of nicardipine therapy on the flow and resist-
ance responses to exercise is shown in Figure 3. There was
no overall effect of nicardipine on either cardiac index or
stroke volume index, when the treatment value was com-
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venous oxygen difference at rest (4.8 ± 0.6 to 3.4 ± 0,9
vol%) and during peak exercise (9.0 ± 1.5 to 8.4 ± 1.9
vol%) (p < 0,02),
Pulmonary wedge pressure response to nicardipine
(Fig. 5). Figure 5 shows rest values. all work load levels
studied and the number of patients achieving each work
load. With nicardipine therapy. the rest pulmonary wedge
pressure was essentially unchanged. However, it was mark-
edly reduced at all ergometric loads, and only minimally
increased compared with the rest pretreatment pulmonary
wedge pressure.
Hormonal responses to nicardipine. Figure 6 sum-
marizes the characteristics of plasma renin activity and plasma
norepinephrine during exercise and in response to nicardi-
pine therapy, While plasma renin activity increased from
1.8 ± 2.4 to 3.0 ± 8.6 ng/ml per h during exercise in the
untreated state, this effect was not statistically significant.
Incontrast, during nicardipine therapy, plasma renin activity
was increased at both rest (5.9 ± 8.4) and peak exercise
(8.4 ± II ng/ml per h) (p < 0.05). In the baseline state,
plasma norepinephrine increased from 398 ± 232 to I ,427
± 840 pg/nl (p < 0.001). An effect of nicardipine on
norepinephrine was present at rest (913 ± 477) and at peak
exercise (2,706 ± 1,586 pg/rnl) (p < 0.00 1). Before treat-
ment, plasma epinephrine (not shown in Fig. 6) was 162
Figure5. The response of pulmonary wedgepressure (PWP) dur-
ing exercise is shown for the baseline (e ) and nicardipine (0)
exercise studies, for all work loads achieved. Atthe lower margin
of the figure is thetotal number (n)of patients who achieved each
level of exercise. and the paired analyses for the nicardipine effect
for each work load. Themean values for the 100and 125 W work
loads are connected by broken lines to identify the major drop-
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Figure 6. The response of plasma renin activity (PRA) and nor-
epinephrine (NE) to exercise (Ex) both before and after I week
of nicardipine (Nic) therapy. A significant effect was observed for
each of the hormonal variables during nicardipine therapy. (e)
Baseline: (0) nicardipine.
± 11 5 pg/ml at rest and 483 ± 651 at peak exercise. After
nicardipine, values were 136 ± 117 pg/ml at rest and 715
± 774 at peak exercise. The effect of exercise was p <
0.03 , whereas the nicardipine effect was not significant.
Side effects. Clinically, nicardipine was tolerated by all
patients in this study. Serum electrolytes, hemogram and
liver and renal function were unchanged. Twenty-four hour
urinary sodium excretion at baseline (88 ± 12 mEg) was
not changed after 1 week of nicardipine (85 ± 13 mEg)
therapy. Body weight was also unchanged (90 ± 7 versus
89 ± 7 kg).
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Discussion
Hemodynamic response to exercise: hypertension ver-
sus normal. There are few studies regarding the cardio-
vascular response to exercise in hypertensive individuals
that consider changes in cardiac fi lling pressures, and a
similar limitation has accompanied previous studies in nor-
mal subjects. However. information regarding the normal
response to exercise was recently provided in a rigorous
study by Higginbotham et al. (24). The findings of these
investigators are particularly relevant in that the exercise
protocol they employed was virtually identical to that of the
present study, so direct comparisons can be made. In the
present study, exercise was associated with a marked in-
crease of both systolic and diastolic blood pressure above
the already elevated baseline values. This increase of blood
pressure was greater than that observed in normal subjects,
but was nonetheless mediated by an increase of cardiac index
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degree, heart rate. In hypertensive patients, calculated sys-
temic vascular resistance during exercise decreased from
the baseline vasoconstricted state, yet the absolute value
achieved was less than that reported in normal subjects,
suggesting adverse vascular adaptation in severe hyperten-
sion that may compromise the response to exercise. An
additional observation was the response of pulmonary wedge
pressure during exercise; mean levels in hypertensive pa-
tients were at least twofold greater than in normal subjects.
These findings emphasize the importance of ergometric ex-
ercise in hypertensive patients, because the abnormal ex-
ercise increase in wedge pressure and the favorable effect
of nicardipine would have been overlooked had only rest
hemodynamic values been obtained. The magnitude of in-
crease of pulmonary wedge pressure in untreated hyperten-
sive patients was also greater than that previously reported
in patients with less severe hypertension (1).
In the present study stroke volume was mildly decreased
compared with that of normal subjects (24), yet was rela-
tively preserved when compared with that of individuals
who had congestive heart failure (25). Because an increase
of left ventricular filling pressure is necessary to maintain
normal stroke volume index during exercise (24), it is pos-
sible that the observed marked increase of pulmonary wedge
pressure in moderate to severe hypertension reflects the
functional adaptation necessary to maintain stroke volume
in the presence of increased afterload. On the other hand,
the increase of pulmonary wedge pressure during exercise
may reflect a reduction of left ventricular compliance, be-
cause this is one of the earliest changes evoked by long-
standing or severe hypertension (26).
Effect of nicardipine on exercise hemodynamics in
hypertension. The hemodynamic response to nicardipine
was characterized by a marked reduction of blood pressure,
mediated by reversal of vasoconstriction, during rest and
peak exercise conditions. The heart rate response was more
complex, in that the rest heart rate was somewhat higher
during nicardipine therapy, whereas peak exercise heart rate
was unchanged. Because these were patients with severe
hypertension, unloading or disinhibiting arterial barorecep-
tors (27) may have been associated with increased sympa-
thetic nervous system activity that was still manifest at I
week of therapy. Alternatively, nicardipine may have di-
rectly stimulated catecholamine release, as previously sug-
gested for other calcium channel antagonists (28-31), and
this would be consistent with the rest heart rate and nor-
epinephrine changes at 1 week of therapy. During exercise,
however, the heart rate response was not appreciably altered
despite the increase of norepinephrine, suggesting that the
heart rate response to the stimulus of exercise was predom-
inant when compared with any coexistent drug-induced ef-
fect. The absence of a more positive or negative effect of
nicardipine on cardiac index was similar to findings with
other vasodilators, such as converting enzyme inhibitors
(32), that have no major direct effect on contractility. Thus,
a clinically significant negative inotropic effect of nicardi-
pine could not be identified.
Of additional importance, was the fact that cardiac index,
in response to exercise, was maintained with markedly re-
duced pulmonary wedge pressure during nicardipine ther-
apy. This was associated with some evidence of a favorable
effect on oxygen utilization, in that overall oxygen extrac-
tion was significantly decreased during nicardipine therapy.
To our knowledge, this degree of reduction of pulmonary
wedge pressure during peak exercise has not previously been
reported with drug therapy of hypertension. This magnitude
of response, for instance, was not observed during acute
captopril therapy (I), and the pulmonary wedge pressure
response to verapamil during exercise, previously reported
by our group (3), was relatively small. Compared with the
normal range of pulmonary wedge pressure response to ex-
ercise, reported by Higginbotham et al. (24), nicardipine
induced a normalization of pulmonary wedge pressure in
moderate to severe hypertension.
Mechanisms influencing the hemodynamic response
to nicardipine. Several potential mechanisms may account
for the maintenance of exercise cardiac index at a markedly
reduced pulmonary wedge pressure during nicardipine ther-
apy. First, there is a marked reduction of arterial afterload,
as evidenced by the decrease of systemic vascular resistance.
Second, there is an improvement of ventricular compliance.
This could occur as a consequence of reduced arterial af-
terload or may be a direct consequence of nicardipine. Ven-
tricular compliance is abnormal in hypertension (26,33-36)
and previous studies (11,37,38) have suggested a favorable
effect of calcium channel antagonists on the compliance
changes of the hypertrophied ventricle. Third, preload may
have been reduced during nicardipine therapy. The lack of
change in urinary sodium excretion and body weight sug-
gests that total blood volume was unaltered, but we cannot
exclude a relative shift of cardiopulmonary blood volume
to the periphery during exercise that, in effect, could lower
preload. It is possible that a combination of these factors
accounted for the observed effect; however, the study design
we utilized cannot distinguish among the relative contri-
butions of these mechanisms. We also cannot extrapolate
these findings to patients with mild hypertension, whose
hemodynamic abnormalities may be less pronounced.
Hormonal responses to nicardipine. Reports of the
response of catecholamines and plasma renin activity to
calcium channel antagonists are somewhat divergent
(3,28-31). The observed increase of rest heart rate in our
study may have been a manifestation of increased sympa-
thetic activity. However, there was no evidence to suggest
that an increase of alpha-adrenergic tone interfered with the
favorable effect of nicardipine on both rest and exercise
systemic vascular resistance, because epinephrine was not
increased. The observed increase of plasma renin activity
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may represent either a direct or an indirect effect of ni-
cardipine. In vitro studies have demonstrated that calcium
channel antagonists will directly induce renin release from
juxtaglomerular cells (39), while at the same time suppress-
ing aldosterone release from the zona glomerulosa (40). An
indirect release of 'renin may have been mediated by the
observed increase of peripheral norepinephrine in the pres-
ent study, because increased renal sympathetic activity is a
recognized stimulus of renin release.
Conclusion. In patients with moderate to severeessential
hypertension, there was a marked increase of blood pressure
and pulmonary wedge pressure in response to ergometric
exercise, with relative preservation of cardiac index. Ni-
cardipine therapy induced a significant reduction of blood
pressure, mediated by reversal of vasoconstriction. Exercise
cardiac index was maintained with markedly reduced pul-
monary wedge pressure during nicardipine therapy and was
associated with reduction of oxygen extraction. The overall
favorable effect of nicardipine was most likely mediated by
the reversal of vasoconstriction. However, we cannot ex-
clude a direct effect of nicardipine on the abnormal com-
pliance changes that accompany ventricular adaptation to
hypertension, or a relative reduction of cardiopulmonary
blood volume.
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